Satellos Bioscience Inc. Common Stock
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.52 | $0 | -$9M |
| 2025 Q4 | -0.48 | $0 | -$7M |
| 2025 Q3 | -0.36 | $0 | -$4M |
| 2025 Q2 | -0.36 | $0 | -$5M |
| 2025 Q1 | -0.48 | $0 | -$7M |
| 2024 Q4 | -0.45 | $0 | -$5M |
| 2024 Q3 |
| -0.98 |
| $0 |
| -$4M |
| 2024 Q2 | -0.47 | $0 | -$4M |